Capital International Inc. CA Boosts Holdings in Abbott Laboratories $ABT

Capital International Inc. CA grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 5.9% during the 4th quarter, HoldingsChannel reports. The fund owned 1,022,306 shares of the healthcare product maker’s stock after acquiring an additional 57,070 shares during the quarter. Abbott Laboratories makes up 1.0% of Capital International Inc. CA’s investment portfolio, making the stock its 24th biggest position. Capital International Inc. CA’s holdings in Abbott Laboratories were worth $128,085,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in ABT. MidAtlantic Capital Management Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $25,000. Harbor Capital Advisors Inc. purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $27,000. Bridge Generations Wealth Management LLC purchased a new position in shares of Abbott Laboratories during the third quarter worth approximately $33,000. Leonteq Securities AG purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $35,000. Finally, Board of the Pension Protection Fund purchased a new position in shares of Abbott Laboratories during the fourth quarter worth approximately $38,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 0.5%

Shares of NYSE ABT opened at $91.20 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06. The firm’s fifty day moving average is $92.80 and its 200 day moving average is $109.31. The company has a market cap of $158.85 billion, a price-to-earnings ratio of 25.55, a PEG ratio of 1.52 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current year.

Analysts Set New Price Targets

ABT has been the topic of several research reports. Wells Fargo & Company decreased their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Barclays decreased their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research note on Monday, April 20th. Piper Sandler decreased their target price on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Leerink Partners decreased their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research note on Tuesday, April 21st. Finally, Stifel Nicolaus decreased their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.09.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is currently owned by insiders.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.